X4 Pharmaceuticals (XFOR) Retained Earnings (2017 - 2026)

X4 Pharmaceuticals (XFOR) has reported Retained Earnings for 10 consecutive years, with -$631.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Retained Earnings fell 16.68% year-over-year to -$631.0 million; the trailing twelve-month figure through Jun 2026 stood at -$631.0 million (down 16.68% YoY), and the FY2025 full-year result was -$594.6 million, down 15.37% from the prior year.
• Retained Earnings slipped to -$631.0 million in Q2 2026 per XFOR's latest filing, from -$614.8 million in the prior quarter.
• Across five years, Retained Earnings topped out at -$304.8 million in Q1 2022 and bottomed at -$631.0 million in Q2 2026.
• Historically, Retained Earnings has averaged -$476.4 million across 5 years, with a median of -$476.7 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Retained Earnings slumped 43.22% in 2022, then climbed 3.87% in 2024.
• Over 5 years, Retained Earnings stood at -$376.7 million in 2022, then dropped by 26.85% to -$477.9 million in 2023, then fell by 7.84% to -$515.4 million in 2024, then fell by 15.37% to -$594.6 million in 2025, then dropped by 6.13% to -$631.0 million in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered -$631.0 million, -$614.8 million, and -$594.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.